Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

Turn­ing a years-long part­ner­ship in­to own­er­ship, Bio­con is shelling out $3.335 bil­lion to buy out Vi­a­tris’ biosim­i­lars busi­ness.

Re­ports first emerged weeks ago about plans to merge the two com­pa­nies’ biosim­i­lars unit in­to a $10 bil­lion stand­alone busi­ness. The bi­o­log­ics group un­der Bio­con, a dom­i­nant gener­ics play­er out of In­dia, had been work­ing with My­lan on de­vel­op­ing biosim­i­lars for the world long be­fore My­lan merged with Pfiz­er’s Up­john to be­come Vi­a­tris. To­geth­er, they boast of many firsts — in­clud­ing launch­ing the first in­ter­change­able biosim­i­lar in the US, for the in­sulin Lan­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER